CJC-1295 + Ipamorelin Blend 20mg – PharmaTech

CJC-1295 + Ipamorelin is a dual-peptide combination designed to investigate complementary mechanisms regulating growth hormone (GH) secretion.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that activates the GHRH receptor (GHRHR) on pituitary somatotroph cells. Ipamorelin is a selective growth hormone secretagogue acting primarily through the growth hormone secretagogue receptor type 1a (GHS-R1a).

The combination therefore provides a research model involving two distinct upstream pathways of the GH axis:

CJC-1295 → GHRHR → GH secretion

Ipamorelin → GHS-R1a → GH secretion

The exact pharmacological profile depends importantly on whether the CJC-1295 component is formulated with DAC or without DAC. Human pharmacokinetic data demonstrating multi-day exposure apply specifically to CJC-1295 with DAC and should not automatically be transferred to the no-DAC form.

OVERVIEW

CJC-1295 + Ipamorelin is a dual-peptide combination designed to investigate complementary mechanisms regulating growth hormone (GH) secretion.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that activates the GHRH receptor (GHRHR) on pituitary somatotroph cells. Ipamorelin is a selective growth hormone secretagogue acting primarily through the growth hormone secretagogue receptor type 1a (GHS-R1a).

The combination therefore provides a research model involving two distinct upstream pathways of the GH axis:

CJC-1295 → GHRHR → GH secretion

Ipamorelin → GHS-R1a → GH secretion

The exact pharmacological profile depends importantly on whether the CJC-1295 component is formulated with DAC or without DAC. Human pharmacokinetic data demonstrating multi-day exposure apply specifically to CJC-1295 with DAC and should not automatically be transferred to the no-DAC form.


MECHANISM OF ACTION

CJC-1295 — GHRH Pathway

CJC-1295 is a modified GHRH analogue designed to stimulate the growth hormone-releasing hormone receptor (GHRHR).

GHRHR activation in pituitary somatotrophs promotes intracellular signaling associated with GH synthesis and secretion. The resulting increase in GH can subsequently stimulate peripheral IGF-1 production and downstream GH/IGF-1 signaling.

For the DAC form, the modification enables prolonged association with circulating albumin, substantially extending systemic exposure compared with shorter-acting GHRH analogues.

Ipamorelin — GHS-R1a Pathway

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts primarily through GHS-R1a, also known as the ghrelin receptor.

Activation of GHS-R1a stimulates pituitary GH secretion through a pathway distinct from GHRHR activation.

Combined Mechanistic Model

The combination can be represented as:

CJC-1295 → GHRHR activation → pituitary somatotroph signaling → GH release

Ipamorelin → GHS-R1a activation → pituitary GH release

GH → GHR activation → IGF-1 production → downstream tissue signaling

This complementary receptor architecture makes the combination relevant to research into GH-axis regulation and endocrine signaling.


KEY BENEFITS

Research applications for the combination include:

  • Investigation of GH secretion
  • Study of complementary GHRH and GHS-R1a pathways
  • GH/IGF-1 axis research
  • Investigation of GH pulsatility
  • Endocrine signaling research
  • Metabolic physiology
  • Body-composition biology
  • Muscle and tissue biology
  • Cellular growth signaling
  • Pituitary GH regulation

Human studies of CJC-1295 with DAC demonstrated sustained increases in GH and IGF-1 in healthy adults, with preserved pulsatile GH secretion in a separate study.


RESEARCH AREAS

Growth Hormone Physiology

Investigation of pituitary GH synthesis, secretion, pulsatility, feedback regulation, and endocrine responses.

GHRH/GHRHR Signaling

Study of GHRH receptor activation and its role in somatotroph GH secretion.

GHS-R1a Signaling

Investigation of ghrelin-receptor-mediated stimulation of GH release.

GH/IGF-1 Axis

Research into the relationship between GH secretion, IGF-1 production, and downstream growth-factor signaling.

Metabolic Research

Investigation of GH-associated pathways involving lipid metabolism, glucose regulation, energy balance, and substrate utilization.

Body Composition

Experimental investigation of GH/IGF-1 signaling in adipose and lean-tissue biology.

Muscle & Tissue Biology

Research into GH- and IGF-1-associated cellular pathways relevant to muscle and connective-tissue physiology.


SCIENTIFIC EVIDENCE

The strongest human evidence within this combination concerns CJC-1295 with DAC. In randomized, placebo-controlled studies of healthy adults, single administration produced dose-dependent increases in mean plasma GH and IGF-1, with estimated CJC-1295 half-lives of approximately 5.8–8.1 days.

A separate human study demonstrated that GH secretion remained pulsatile following CJC-1295 administration, while basal and mean GH concentrations increased and IGF-1 concentrations rose.

The pharmacological rationale for combining CJC-1295 and Ipamorelin derives from their different receptor targets: GHRHR for CJC-1295 and GHS-R1a for Ipamorelin. However, evidence directly evaluating a specific fixed-ratio CJC-1295 + Ipamorelin formulation is substantially more limited than the evidence available for CJC-1295 alone.

For this reason, component-level evidence should be distinguished from clinical evidence specifically validating the combined PharmaTech formulation.


MOLECULAR PROFILE

Parameter CJC-1295 Ipamorelin
Compound class Modified GHRH analogue Synthetic GH secretagogue
Primary target GHRH receptor (GHRHR) GHS-R1a
Peptide length Modified GRF(1–29) 5 amino acids
Primary pathway GHRH/GH axis Ghrelin/GH axis
Major downstream mediator GH → IGF-1 GH → IGF-1
Molecular weight Form-dependent ~711.9 Da
DAC modification Form-dependent Not applicable
Biological focus Pituitary GH stimulation Pituitary GH stimulation

Ipamorelin Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH₂

CJC-1295

CJC-1295 is a modified GHRH(1–29)-related peptide containing amino-acid substitutions designed to improve resistance to enzymatic degradation. The DAC version additionally incorporates the drug-affinity complex responsible for prolonged albumin association.


PHARMACOKINETIC & PHARMACODYNAMIC PROFILE

Pharmacokinetic Profile

The pharmacokinetic characteristics depend substantially on the CJC-1295 variant.

For CJC-1295 with DAC, human studies reported an estimated half-life of approximately 5.8–8.1 days, with measurable concentrations persisting for multiple days after administration.

By contrast, published human pharmacokinetic data for CJC-1295 without DAC are considerably more limited. Therefore, pharmacokinetic values established for the DAC variant should not automatically be applied to a no-DAC formulation.

Ipamorelin has a substantially different pharmacological profile because it acts as a GHS-R1a agonist rather than a long-acting GHRH analogue.

The pharmacokinetic profile of the complete PharmaTech blend ultimately depends on:

  • CJC-1295 variant
  • CJC-1295/Ipamorelin ratio
  • Formulation
  • Concentration
  • Peptide purity
  • Route of administration
  • Product-specific stability characteristics

Pharmacodynamic Profile

The principal signaling cascade can be summarized as:

CJC-1295 → GHRHR → pituitary somatotroph → GH secretion

Ipamorelin → GHS-R1a → pituitary somatotroph → GH secretion

GH → GHR → IGF-1 → peripheral biological signaling

Human CJC-1295 DAC studies demonstrated sustained increases in GH and IGF-1, while preserving the pulsatile nature of GH secretion.


RESEARCH HIGHLIGHTS

  • Dual-pathway GH secretagogue system
  • GHRHR and GHS-R1a pathway research
  • Investigation of endogenous GH secretion
  • GH pulsatility research
  • GH/IGF-1 axis modulation
  • Pituitary endocrine signaling
  • Metabolic signaling research
  • Body-composition biology
  • Muscle and tissue research
  • Comparative investigation of GHRH and ghrelin pathways

TECHNICAL SPECIFICATIONS

Parameter PharmaTech Specification
Product CJC-1295 + Ipamorelin Blend
Product type Synthetic peptide blend
Components CJC-1295 + Ipamorelin
CJC-1295 variant [DAC / No-DAC — PharmaTech specification]
Total quantity [PharmaTech specification]
Ratio [PharmaTech specification]
CJC-1295 content [PharmaTech specification]
Ipamorelin content [PharmaTech specification]
Purity ≥ [PharmaTech specification]%
Physical form Lyophilized powder
Container Sterile sealed vial
Appearance White to off-white lyophilized material
Batch [Batch specification]
Storage Controlled refrigerated storage
Research category GH / GHRH / GHS-R1a / IGF-1 signaling

STORAGE & HANDLING

Store the lyophilized product under controlled conditions according to the applicable PharmaTech product specification.

Protect from:

  • Excessive heat
  • Direct light
  • Moisture
  • Repeated temperature fluctuations
  • Physical contamination

Keep the container sealed until laboratory use and handle under appropriate controlled conditions.